{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T12:17:22Z","timestamp":1784290642349,"version":"3.55.0"},"reference-count":168,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ibroneuroscience.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuroscience"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.neuroscience.2026.05.037","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T15:18:12Z","timestamp":1780586292000},"page":"22-35","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Understanding resistance in glioblastoma: insights into personalized and targeted therapeutic strategies"],"prefix":"10.1016","volume":"610","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-9424-7188","authenticated-orcid":false,"given":"Nourhan E.","family":"Omran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruba A.","family":"Zenati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara J.","family":"Bou Malhab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasser","family":"Bustanji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karem H.","family":"Alzoubi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rania","family":"Harati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad H.","family":"Semreen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuroscience.2026.05.037_b0005","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1158\/0008-5472.CAN-18-1733","article-title":"Temozolomide induces senescence and repression of DNA repair pathways in glioblastoma cells via activation of ATR\u2013Chk1, p21, and NF-kB","volume":"79","author":"Aasland","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.neuroscience.2026.05.037_b0010","doi-asserted-by":"crossref","first-page":"289","DOI":"10.3389\/fonc.2014.00289","article-title":"A small-molecule inhibitor of RAD51 reduces homologous recombination and sensitizes multiple myeloma cells to doxorubicin","volume":"4","author":"Alagpulinsa","year":"2014","journal-title":"Front. Oncol."},{"issue":"7","key":"10.1016\/j.neuroscience.2026.05.037_b0015","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1038\/cdd.2014.31","article-title":"Conversion of differentiated cancer cells into cancer stem-like cells in a glioblastoma model after primary chemotherapy","volume":"21","author":"Auffinger","year":"2014","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.neuroscience.2026.05.037_b0020","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1038\/s41591-024-02893-z","article-title":"Intrathecal bivalent CAR T cells targeting EGFR and IL13R\u03b12 in recurrent glioblastoma: phase 1 trial interim results","volume":"30","author":"Bagley","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.neuroscience.2026.05.037_b0025","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1021\/acs.jmedchem.9b01526","article-title":"Synthetic lethality in pancreatic cancer: discovery of a new RAD51-BRCA2 small molecule disruptor that inhibits homologous recombination and synergizes with olaparib","volume":"63","author":"Bagnolini","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuroscience.2026.05.037_b0030","unstructured":"Baker, S. D., Wirth, M., Statkevich, P., Reidenberg, P., Alton, K., Sartorius, S. E., Dugan, M., Cutler, D., Batra, V., Grochow, L. B., Donehower, R. C., & Rowinsky, E. K. (1999). Absorption, Metabolism, and Excretion of 14 C-Temozolomide following Oral Administration to Patients with Advanced Cancer 1. http:\/\/aacrjournals.org\/clincancerres\/article-pdf\/5\/2\/309\/2071717\/df029900309.pdf."},{"key":"10.1016\/j.neuroscience.2026.05.037_b0035","doi-asserted-by":"crossref","first-page":"6043","DOI":"10.1158\/0008-5472.CAN-08-1079","article-title":"Targeting cancer stem cells through L1CAM suppresses glioma growth","volume":"68","author":"Bao","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.neuroscience.2026.05.037_b0040","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/nature05236","article-title":"Glioma stem cells promote radioresistance by preferential activation of the DNA damage response","volume":"444","author":"Bao","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.neuroscience.2026.05.037_b0045","doi-asserted-by":"crossref","first-page":"7843","DOI":"10.1158\/0008-5472.CAN-06-1010","article-title":"Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor","volume":"66","author":"Bao","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.neuroscience.2026.05.037_b0050","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrg1272","article-title":"Network biology: understanding the cell\u2019s functional organization","volume":"5","author":"Barab\u00e1si","year":"2004","journal-title":"In Nature Reviews Genetics (vol."},{"key":"10.1016\/j.neuroscience.2026.05.037_b0055","doi-asserted-by":"crossref","unstructured":"Bian, L., Meng, Y., Zhang, M., & Li, D. (2019). MRE11-RAD50-NBS1 complex alterations and DNA damage response: Implications for cancer treatment. In Molecular Cancer (Vol. 18). BioMed Central Ltd. https:\/\/doi.org\/10.1186\/s12943-019-1100-5.","DOI":"10.1186\/s12943-019-1100-5"},{"key":"10.1016\/j.neuroscience.2026.05.037_b0060","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1093\/neuonc\/nox182","article-title":"Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma","volume":"20","author":"Bielamowicz","year":"2018","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.neuroscience.2026.05.037_b0065","doi-asserted-by":"crossref","first-page":"340","DOI":"10.4103\/crst.crst_250_23","article-title":"Glioblastoma multiforme - a rare type of cancer: a narrative review","volume":"7","author":"Bijalwan","year":"2024","journal-title":"Cancer Research, Statistics, and Treatment"},{"key":"10.1016\/j.neuroscience.2026.05.037_b0070","doi-asserted-by":"crossref","unstructured":"Bonilla, B., Hengel, S. R., Grundy, M. K., & Bernstein, K. A. (2020). RAD51 Gene Family Structure and Function. In Annual Review of Genetics (Vol. 54, pp. 25\u201346). Annual Reviews Inc. https:\/\/doi.org\/10.1146\/annurev-genet-021920-092410.","DOI":"10.1146\/annurev-genet-021920-092410"},{"key":"10.1016\/j.neuroscience.2026.05.037_b0075","doi-asserted-by":"crossref","unstructured":"Boyd, N. H., Tran, A. N., Bernstock, J. D., Etminan, T., Jones, A. B., Yancey Gillespie, G., Friedman, G. K., & Hjelmeland, A. B. (2020). Glioma stem cells and their roles within the hypoxic tumor microenvironment. In Theranostics (Vol. 11, pp. 665\u2013683). Ivyspring International Publisher. https:\/\/doi.org\/10.7150\/thno.41692.","DOI":"10.7150\/thno.41692"},{"key":"10.1016\/j.neuroscience.2026.05.037_b0080","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","article-title":"Regression of glioblastoma after chimeric antigen receptor T-cell therapy","volume":"375","author":"Brown","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neuroscience.2026.05.037_b0085","doi-asserted-by":"crossref","unstructured":"Butler, M., Pongor, L., Su, Y. T., Xi, L., Raffeld, M., Quezado, M., Trepel, J., Aldape, K., Pommier, Y., & Wu, J. (2020). MGMT Status as a Clinical Biomarker in Glioblastoma. In Trends in Cancer (Vol. 6, Number 5, pp. 380\u2013391). Cell Press. https:\/\/doi.org\/10.1016\/j.trecan.2020.02.010.","DOI":"10.1016\/j.trecan.2020.02.010"},{"key":"10.1016\/j.neuroscience.2026.05.037_b0090","doi-asserted-by":"crossref","unstructured":"Caldecott, K. W. (2003). XRCC1 and DNA strand break repair. In DNA Repair (Vol. 2, pp. 955\u2013969). Elsevier. https:\/\/doi.org\/10.1016\/S1568-7864(03)00118-6.","DOI":"10.1016\/S1568-7864(03)00118-6"},{"key":"10.1016\/j.neuroscience.2026.05.037_b0095","doi-asserted-by":"crossref","DOI":"10.1186\/s13046-019-1204-1","article-title":"Olaparib and ionizing radiation trigger a cooperative DNA-damage repair response that is impaired by depletion of the VRK1 chromatin kinase","volume":"38","author":"Campillo-Marcos","year":"2019","journal-title":"Journal of Experimental and Clinical Cancer Research"},{"key":"10.1016\/j.neuroscience.2026.05.037_b0100","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1200\/JCO.2018.36.15_suppl.2018","article-title":"Phase I clinical trials evaluating olaparib in combination with radiotherapy (RT) and\/or temozolomide (TMZ) in glioblastoma patients: results of OPARATIC and PARADIGM phase I and early results of PARADIGM-2","volume":"36","author":"Chalmers","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.neuroscience.2026.05.037_b0105","doi-asserted-by":"crossref","first-page":"4309","DOI":"10.3892\/mmr.2015.3279","article-title":"Tumor formation and drug resistance properties of human glioblastoma side population cells","volume":"11","author":"Chen","year":"2015","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.neuroscience.2026.05.037_b0110","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14194942","article-title":"Roles of chromatin remodelling and molecular heterogeneity in therapy resistance in glioblastoma","volume":"14","author":"Chen","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.neuroscience.2026.05.037_b0115","doi-asserted-by":"crossref","DOI":"10.1093\/neuonc\/noy016","article-title":"Temozolomide-associated hypermutation in gliomas","author":"Choi","year":"2018","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.neuroscience.2026.05.037_b0120","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.11275","article-title":"Downregulation of both mismatch repair and non-homologous end-joining pathways in hypoxic brain tumour cell lines","volume":"9","author":"Cowman","year":"2021","journal-title":"PeerJ"},{"key":"10.1016\/j.neuroscience.2026.05.037_b0125","doi-asserted-by":"crossref","unstructured":"Cristiana, B., Miriam, P., Linda, S., Alessia, M., Laura, R., Simone, G., Alexandra, B.-S., Sara, M., & Silvia K, N. (2018). Sox2 Functions in Neural Cancer Stem Cells: The Importance of the Context. Insights of Neuro Oncology, 2(1). https:\/\/doi.org\/10.36959\/828\/332.","DOI":"10.36959\/828\/332"},{"issue":"7274","key":"10.1016\/j.neuroscience.2026.05.037_b0130","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/nature08617","article-title":"Cancer-associated IDH1 mutations produce 2-hydroxyglutarate","volume":"462","author":"Dang","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.neuroscience.2026.05.037_b0135","doi-asserted-by":"crossref","first-page":"MDPI","DOI":"10.3390\/cells10092257","article-title":"The interplay between glioblastoma and its microenvironment. In","volume":"10","author":"Dapash","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.neuroscience.2026.05.037_b0140","unstructured":"David Reardon, MD, & Dana-Farber Cancer Institute. (2026, April 17). Study Details | NCT02287428 | Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM | ClinicalTrials.gov. Https:\/\/Clinicaltrials.Gov\/Study\/NCT02287428. https:\/\/clinicaltrials.gov\/study\/NCT02287428."},{"key":"10.1016\/j.neuroscience.2026.05.037_b0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1188\/16.CJON.S1.2-8","article-title":"Glioblastoma: overview of disease and treatment","volume":"20","author":"Davis","year":"2016","journal-title":"Clin. J. Oncol. Nurs."},{"key":"10.1016\/j.neuroscience.2026.05.037_b0150","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1158\/1078-0432.CCR-06-2854","article-title":"The blood-brain barrier and cancer: transporters, treatment, and trojan horses. In","volume":"13","author":"Deeken","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.neuroscience.2026.05.037_b0155","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-09853-z","article-title":"Stem cell-associated heterogeneity in glioblastoma results from intrinsic tumor plasticity shaped by the microenvironment","volume":"10","author":"Dirkse","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.neuroscience.2026.05.037_b0160","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.1038\/sj.onc.1209302","article-title":"CXCR4 expression mediates glioma cell invasiveness","volume":"25","author":"Ehtesham","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.neuroscience.2026.05.037_b0165","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0185085","article-title":"The warburg effect as an adaptation of cancer cells to rapid fluctuations in energy demand","volume":"12","author":"Epstein","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.neuroscience.2026.05.037_b0170","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2013.388","article-title":"O6-methylguanine DNA methyltransferase as a promising target for the treatment of temozolomide-resistant gliomas. In","volume":"4","author":"Fan","year":"2013","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.neuroscience.2026.05.037_b0175","doi-asserted-by":"crossref","DOI":"10.1186\/s12935-021-01953-5","article-title":"Predictive value of RAD51 on the survival and drug responsiveness of ovarian cancer","volume":"21","author":"Feng","year":"2021","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.neuroscience.2026.05.037_b0180","doi-asserted-by":"crossref","first-page":"MDPI","DOI":"10.3390\/ijms23094670","article-title":"A2B5 expression in central nervous system and gliomas. In","volume":"23","author":"Figarella-Branger","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuroscience.2026.05.037_b0185","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.dnarep.2006.10.008","article-title":"Base damage and single-strand break repair: mechanisms and functional significance of short- and long-patch repair subpathways","volume":"6","author":"Fortini","year":"2007","journal-title":"DNA Repair"},{"key":"10.1016\/j.neuroscience.2026.05.037_b0190","unstructured":"Friedman, H. S., Kerby, T., & Calvert, H. (2000). Temozolomide and Treatment of Malignant Glioma 1. http:\/\/aacrjournals.org\/clincancerres\/article-pdf\/6\/7\/2585\/2077982\/df070002585.pdf."},{"key":"10.1016\/j.neuroscience.2026.05.037_b0195","article-title":"Temozolomide treatment induces HMGB1 to promote the formation of glioma stem cells via the TLR2\/NEAT1\/Wnt pathway in glioblastoma","volume":"9","author":"Gao","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.neuroscience.2026.05.037_b0200","doi-asserted-by":"crossref","unstructured":"Garnier, D., Renoult, O., Alves-Guerra, M. C., Paris, F., & Pecqueur, C. (2019). Glioblastoma stem-like cells, Metabolic strategy to kill a challenging target. In Frontiers in Oncology (Vol. 9). Frontiers Media S.A. https:\/\/doi.org\/10.3389\/fonc.2019.00118.","DOI":"10.3389\/fonc.2019.00118"},{"issue":"3","key":"10.1016\/j.neuroscience.2026.05.037_b0205","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1001\/jamaneurol.2022.4924","article-title":"Challenges and opportunities for clinical trials in patients with glioma","volume":"80","author":"Gonzalez Castro","year":"2023","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.neuroscience.2026.05.037_b0210","first-page":"MDPI","article-title":"Epidemiology of glioblastoma multiforme\u2013literature review. In","volume":"Vol. 14, Number 10","author":"Grochans","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.neuroscience.2026.05.037_b0215","first-page":"547","article-title":"Does MDR1 promoter methylation affect temozolomide resistance? A clinical study in patients with glioblastoma","volume":"15","author":"G\u00fcner","year":"2022","journal-title":"Pamukkale Medical Journal"},{"key":"10.1016\/j.neuroscience.2026.05.037_b0220","doi-asserted-by":"crossref","unstructured":"Han, S., Liu, Y., Cai, S. J., Qian, M., Ding, J., Larion, M., Gilbert, M. R., & Yang, C. (2020). IDH mutation in glioma: molecular mechanisms and potential therapeutic targets. In British Journal of Cancer (Vol. 122, Number 11, pp. 1580\u20131589). Springer Nature. https:\/\/doi.org\/10.1038\/s41416-020-0814-x.","DOI":"10.1038\/s41416-020-0814-x"},{"key":"10.1016\/j.neuroscience.2026.05.037_b0225","unstructured":"Hanif, F., Muzaffar, K., Perveen, K., Malhi, S. M., & Simjee, S. U. (2017). Glioblastoma multiforme: A review of its epidemiology and pathogenesis through clinical presentation and treatment. In Asian Pacific Journal of Cancer Prevention (Vol. 18, pp. 3\u20139). Asian Pacific Organization for Cancer Prevention. https:\/\/doi.org\/10.22034\/APJCP.2017.18.1.3."},{"key":"10.1016\/j.neuroscience.2026.05.037_b0230","doi-asserted-by":"crossref","unstructured":"He, J., Yan, X., & Hu, S. (2025). Glioma stem cells: drivers of tumor progression and recurrence. In Stem Cell Research and Therapy (Vol. 16). BioMed Central Ltd. https:\/\/doi.org\/10.1186\/s13287-025-04352-z.","DOI":"10.1186\/s13287-025-04352-z"},{"key":"10.1016\/j.neuroscience.2026.05.037_b0235","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-10493-6","article-title":"Tumor-associated reactive astrocytes aid the evolution of immunosuppressive environment in glioblastoma","volume":"10","author":"Henrik Heiland","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.neuroscience.2026.05.037_b0240","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/nature00922","article-title":"The Rad50 zinc-hook is a structure joining Mre11 complexes in DNA recombination and repair","volume":"418","author":"Hopfner","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.neuroscience.2026.05.037_b0245","article-title":"Novel collagen membrane formulations with irinotecan or minocycline for potential application in brain cancer","volume":"17","author":"Idu","year":"2024","journal-title":"Materials (Basel, Switzerland)"},{"key":"10.1016\/j.neuroscience.2026.05.037_b0250","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1093\/brain\/aws330","article-title":"Epigenetic transcriptional activation of monocyte chemotactic protein 3 contributes to long-lasting neuropathic pain","volume":"136","author":"Imai","year":"2013","journal-title":"Brain"},{"key":"10.1016\/j.neuroscience.2026.05.037_b0255","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15194898","article-title":"A narrative review on CD44\u2019s role in glioblastoma invasion, proliferation, and tumor recurrence","volume":"15","author":"Inoue","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.neuroscience.2026.05.037_b0260","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1089\/hum.2021.173","article-title":"Choosing the right tool for genetic engineering: clinical lessons from chimeric antigen receptor-T cells","volume":"32","author":"Irving","year":"2021","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.neuroscience.2026.05.037_b0265","article-title":"Repurposing the antihypertensive agent hydralazine as an inhibitor of the base excision repair enzyme APE1","author":"Islam","year":"2024","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.neuroscience.2026.05.037_b0270","doi-asserted-by":"crossref","unstructured":"Jin, M. H., & Oh, D. Y. (2019). ATM in DNA repair in cancer. In Pharmacology and Therapeutics (Vol. 203). Elsevier Inc. https:\/\/doi.org\/10.1016\/j.pharmthera.2019.07.002.","DOI":"10.1016\/j.pharmthera.2019.07.002"},{"key":"10.1016\/j.neuroscience.2026.05.037_b0275","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.bbrc.2013.03.021","article-title":"Cell surface Nestin is a biomarker for glioma stem cells","volume":"433","author":"Jin","year":"2013","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.neuroscience.2026.05.037_b0280","doi-asserted-by":"crossref","unstructured":"Johnson, A. L., Laterra, J., & Lopez-Bertoni, H. (2022). Exploring glioblastoma stem cell heterogeneity: Immune microenvironment modulation and therapeutic opportunities. In Frontiers in Oncology (Vol. 12). Frontiers Media S.A. https:\/\/doi.org\/10.3389\/fonc.2022.995498.","DOI":"10.3389\/fonc.2022.995498"},{"key":"10.1016\/j.neuroscience.2026.05.037_b0285","doi-asserted-by":"crossref","unstructured":"Ju, F., Atyah, M. M., Horstmann, N., Gul, S., Vago, R., Bruns, C. J., Zhao, Y., Dong, Q. Z., & Ren, N. (2022). Characteristics of the cancer stem cell niche and therapeutic strategies. In Stem Cell Research and Therapy (Vol. 13). BioMed Central Ltd. https:\/\/doi.org\/10.1186\/s13287-022-02904-1.","DOI":"10.1186\/s13287-022-02904-1"},{"key":"10.1016\/j.neuroscience.2026.05.037_b0290","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.molcel.2012.05.052","article-title":"Quantitative live cell imaging reveals a gradual shift between DNA repair mechanisms and a maximal use of HR in mid S phase","volume":"47","author":"Karanam","year":"2012","journal-title":"Mol. Cell"},{"key":"10.1016\/j.neuroscience.2026.05.037_b0295","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41586-018-0792-9","article-title":"Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial","volume":"565","author":"Keskin","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.neuroscience.2026.05.037_b0300","first-page":"1417","article-title":"Expression of the DNA repair enzyme, N-methylpurine-DNA glycosylase (MPG) in astrocytic tumors","volume":"23","author":"Kim","year":"2003","journal-title":"Anticancer Res"},{"key":"10.1016\/j.neuroscience.2026.05.037_b0305","doi-asserted-by":"crossref","unstructured":"Kim, Y.-J., & M. Wilson III, D. (2011). Overview of Base Excision Repair Biochemistry. Current Molecular Pharmacology, 5, 3\u201313. https:\/\/doi.org\/10.2174\/1874467211205010003.","DOI":"10.2174\/1874467211205010003"},{"key":"10.1016\/j.neuroscience.2026.05.037_b0310","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.stemcr.2016.12.005","article-title":"RAD51 is a selective DNA repair target to radiosensitize glioma stem cells","volume":"8","author":"King","year":"2017","journal-title":"Stem Cell Rep."},{"key":"10.1016\/j.neuroscience.2026.05.037_b0315","doi-asserted-by":"crossref","first-page":"5678","DOI":"10.1093\/nar\/gkn550","article-title":"Gamma-H2AX in recognition and signaling of DNA double-strand breaks in the context of chromatin","volume":"36","author":"Kinner","year":"2008","journal-title":"In Nucleic Acids Research (vol."},{"key":"10.1016\/j.neuroscience.2026.05.037_b0320","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1101\/cshperspect.a012583","article-title":"Base excision repair","volume":"5","author":"Krokan","year":"2013","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.neuroscience.2026.05.037_b0325","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.stem.2010.02.018","article-title":"Integrin alpha 6 regulates glioblastoma stem cells","volume":"6","author":"Lathia","year":"2010","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.neuroscience.2026.05.037_b0330","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-51315-8","article-title":"A real-world observation of patients with glioblastoma treated with a personalized peptide vaccine","volume":"15","author":"Latzer","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.neuroscience.2026.05.037_b0335","doi-asserted-by":"crossref","unstructured":"Lebelo, M. T., Joubert, A. M., & Visagie, M. H. (2019). Warburg effect and its role in tumourigenesis. In Archives of Pharmacal Research (Vol. 42, pp. 833\u2013847). Pharmaceutical Society of Korea. https:\/\/doi.org\/10.1007\/s12272-019-01185-2.","DOI":"10.1007\/s12272-019-01185-2"},{"issue":"1","key":"10.1016\/j.neuroscience.2026.05.037_b0340","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1056442","article-title":"Hypoxia induces macrophage polarization and re-education toward an M2 phenotype in U87 and U251 glioblastoma models","volume":"5","author":"Leblond","year":"2016","journal-title":"OncoImmunology"},{"issue":"1","key":"10.1016\/j.neuroscience.2026.05.037_b0345","doi-asserted-by":"crossref","DOI":"10.1080\/17590914.2024.2422268","article-title":"Amino acid and glucose fermentation maintain ATP content in mouse and human malignant glioma cells","volume":"16","author":"Lee","year":"2024","journal-title":"ASN Neuro"},{"key":"10.1016\/j.neuroscience.2026.05.037_b0350","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-019-5413-y","article-title":"Phase I\/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable or partially resectable glioblastoma: OLA-TMZ-RTE-01 trial protocol","volume":"19","author":"Lesueur","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.neuroscience.2026.05.037_b0355","article-title":"Comparative analysis of matrix metalloproteinase family members reveals that MMP9 predicts survival and response to temozolomide in patients with primary glioblastoma","volume":"11","author":"Li","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.neuroscience.2026.05.037_b0360","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/jso.22018","article-title":"Elevated expression of Rad51 is correlated with decreased survival in resectable esophageal squamous cell carcinoma","volume":"104","author":"Li","year":"2011","journal-title":"J. Surg. Oncol."},{"key":"10.1016\/j.neuroscience.2026.05.037_b0365","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.neuron.2007.01.009","article-title":"Olig2-regulated lineage-restricted pathway controls replication competence in neural stem cells and malignant glioma","volume":"53","author":"Ligon","year":"2007","journal-title":"Neuron"},{"issue":"APR","key":"10.1016\/j.neuroscience.2026.05.037_b0370","article-title":"Distinct tumor microenvironment at tumor edge as a result of astrocyte activation is associated with therapeutic resistance for brain tumor","volume":"9","author":"Lin","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.neuroscience.2026.05.037_b0375","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/760679","article-title":"Aberrant expression of N-methylpurine-DNA glycosylase influences patient survival in malignant gliomas","volume":"2012","author":"Liu","year":"2012","journal-title":"J. Biomed. Biotechnol."},{"key":"10.1016\/j.neuroscience.2026.05.037_b0380","article-title":"EZH2 phosphorylation promotes self-renewal of glioma stem-like cells through NF-\u03baB methylation","volume":"9","author":"Liu","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.neuroscience.2026.05.037_b0385","doi-asserted-by":"crossref","unstructured":"Liu, J., Cao, S., Imbach, K. J., Gritsenko, M. A., Lih, T. S. M., Kyle, J. E., Yaron-Barir, T. M., Binder, Z. A., Li, Y., Strunilin, I., Wang, Y. T., Tsai, C. F., Ma, W., Chen, L., Clark, N. M., Shinkle, A., Naser Al Deen, N., Caravan, W., Houston, A., \u2026 Ding, L. (2024). Multi-scale signaling and tumor evolution in high-grade gliomas. Cancer Cell, 42, 1217-1238.e19. https:\/\/doi.org\/10.1016\/j.ccell.2024.06.004.","DOI":"10.1016\/j.ccell.2024.06.004"},{"key":"10.1016\/j.neuroscience.2026.05.037_b0390","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/nrg2345","article-title":"DNA polymerases and human disease","volume":"9","author":"Loeb","year":"2008","journal-title":"In Nature Reviews Genetics (vol."},{"issue":"2","key":"10.1016\/j.neuroscience.2026.05.037_b0395","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/path.1706","article-title":"Molecular mechanisms of drug resistance","volume":"205","author":"Longley","year":"2005","journal-title":"In Journal of Pathology (vol."},{"key":"10.1016\/j.neuroscience.2026.05.037_b0400","doi-asserted-by":"crossref","unstructured":"Lu, Y., Liu, Y., Pang, Y., Pacak, K., & Yang, C. (2018). Double-barreled gun: Combination of PARP inhibitor with conventional chemotherapy. In Pharmacology and Therapeutics (Vol. 188, pp. 168\u2013175). Elsevier Inc. https:\/\/doi.org\/10.1016\/j.pharmthera.2018.03.006.","DOI":"10.1016\/j.pharmthera.2018.03.006"},{"key":"10.1016\/j.neuroscience.2026.05.037_b0405","doi-asserted-by":"crossref","first-page":"MDPI","DOI":"10.3390\/cancers15051414","article-title":"CAR T cell therapy in glioblastoma: overcoming challenges related to antigen expression. In","volume":"15","author":"Luksik","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.neuroscience.2026.05.037_b0410","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1038\/sj.onc.1203578","article-title":"DNA repair and recombination factor Rad51 is over-expressed in human pancreatic adenocarcinoma","volume":"19","author":"Maacke","year":"2000","journal-title":"Oncogene"},{"key":"10.1016\/j.neuroscience.2026.05.037_b0415","unstructured":"MacKenzie D. J. (1926). A Classification of the Tumours of the Glioma Group on a Histogenetic Basis With a Correlated Study of Prognosis. Canadian Medical Association Journal, (872)."},{"issue":"11","key":"10.1016\/j.neuroscience.2026.05.037_b0420","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.molmed.2005.09.004","article-title":"DNA repair inhibition: a selective tumour targeting strategy","volume":"11","author":"Madhusudan","year":"2005","journal-title":"In Trends in Molecular Medicine (vol."},{"key":"10.1016\/j.neuroscience.2026.05.037_b0425","doi-asserted-by":"crossref","unstructured":"Marcucci, F., Corti, A., & Ferreri, A. J. M. (2021). Breaching the blood\u2013brain tumor barrier for tumor therapy. In Cancers (Vol. 13). MDPI AG. https:\/\/doi.org\/10.3390\/cancers13102391.","DOI":"10.3390\/cancers13102391"},{"key":"10.1016\/j.neuroscience.2026.05.037_b0430","doi-asserted-by":"crossref","unstructured":"Marei, H. E., Hasan, A., Pozzoli, G., & Cenciarelli, C. (2023). Cancer immunotherapy with immune checkpoint inhibitors (ICIs): potential, mechanisms of resistance, and strategies for reinvigorating T cell responsiveness when resistance is acquired. In Cancer Cell International (Vol. 23). BioMed Central Ltd. https:\/\/doi.org\/10.1186\/s12935-023-02902-0.","DOI":"10.1186\/s12935-023-02902-0"},{"key":"10.1016\/j.neuroscience.2026.05.037_b0435","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14112655","article-title":"Crosstalk of epigenetic and metabolic signaling underpinning glioblastoma pathogenesis","volume":"14","author":"Markouli","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.neuroscience.2026.05.037_b0440","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-019-1477-5","article-title":"The lncRNA TP73-AS1 is linked to aggressiveness in glioblastoma and promotes temozolomide resistance in glioblastoma cancer stem cells","volume":"10","author":"Mazor","year":"2019","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.neuroscience.2026.05.037_b0445","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1111\/j.1365-2559.2009.03448.x","article-title":"Overexpression of RAD51 occurs in aggressive prostatic cancer","volume":"55","author":"Mitra","year":"2009","journal-title":"Histopathology"},{"key":"10.1016\/j.neuroscience.2026.05.037_b0450","doi-asserted-by":"crossref","unstructured":"Mohanty, R., Chowdhury, C. R., Arega, S., Sen, P., Ganguly, P., & Ganguly, N. (2019). CAR T cell therapy: A new era for cancer treatment (Review). In Oncology Reports (Vol. 42, pp. 2183\u20132195). Spandidos Publications. https:\/\/doi.org\/10.3892\/or.2019.7335.","DOI":"10.3892\/or.2019.7335"},{"key":"10.1016\/j.neuroscience.2026.05.037_b0455","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13215358","article-title":"Expression levels of rad51 inversely correlate with survival of glioblastoma patients","volume":"13","author":"Morrison","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.neuroscience.2026.05.037_b0460","article-title":"Targeting DNA repair pathways in orthotopic glioblastoma xenoplants","author":"M\u00fcller","year":"2024","journal-title":"Journal of Oncology Research and Therapy."},{"key":"10.1016\/j.neuroscience.2026.05.037_b0465","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/j.metabol.2014.10.031","article-title":"Biomarkers of glioblastoma multiforme","volume":"64","author":"Nicolaidis","year":"2015","journal-title":"Metab. Clin. Exp."},{"issue":"19","key":"10.1016\/j.neuroscience.2026.05.037_b0470","doi-asserted-by":"crossref","first-page":"6002","DOI":"10.1158\/1078-0432.CCR-09-0715","article-title":"IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas","volume":"15","author":"Nobusawa","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.neuroscience.2026.05.037_b0475","first-page":"199","article-title":"Gene silencing of HIF-2\u03b1 disrupts glioblastoma stem cell phenotype","volume":"3","author":"Nusblat","year":"2020","journal-title":"Cancer Drug Resistance (Alhambra, Calif.)"},{"key":"10.1016\/j.neuroscience.2026.05.037_b0480","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/0006-2952(95)00082-B","article-title":"In vivo and in vitro evidence for ATP-dependency of P-glycoprotein-mediated efflux of doxorubicin at the blood-brain barrier","volume":"49","author":"Ohnishi","year":"1995","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuroscience.2026.05.037_b0485","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa0984","article-title":"A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma","volume":"9","author":"O\u2019Rourke","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.neuroscience.2026.05.037_b0490","first-page":"513","article-title":"Temozolomide: an updated overview of resistance mechanisms, nanotechnology advances and clinical applications","volume":"19","author":"Ortiz","year":"2020","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.neuroscience.2026.05.037_b0495","doi-asserted-by":"crossref","unstructured":"Ostrom, Q. T., Gittleman, H., Farah, P., Ondracek, A., Chen, Y., Wolinsky, Y., Stroup, N. E., Kruchko, C., & Barnholtz-Sloan, J. S. (2013). CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. Neuro-Oncology, 15(SUPPL.2). https:\/\/doi.org\/10.1093\/neuonc\/not151.","DOI":"10.1093\/neuonc\/not151"},{"key":"10.1016\/j.neuroscience.2026.05.037_b0500","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1602\/neurorx.2.1.3","article-title":"The blood-brain barrier: bottleneck in brain drug development","volume":"2","author":"Pardridge","year":"2005","journal-title":"NeuroRx"},{"key":"10.1016\/j.neuroscience.2026.05.037_b0505","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.gene.2018.10.069","article-title":"Comprehensive analysis of reverse phase protein array data reveals characteristic unique proteomic signatures for glioblastoma subtypes","volume":"685","author":"Patil","year":"2019","journal-title":"Gene"},{"key":"10.1016\/j.neuroscience.2026.05.037_b0510","doi-asserted-by":"crossref","unstructured":"Piotrowski, A., Puduvalli, V., Wen, P., Campian, J., Colman, H., Pearlman, M., Butowski, N., Battiste, J., Glass, J., Cloughesy, T., Schiff, D., van den Bent, M., Walbert, T., Ahluwalia, M., Badruddoja, M., Kalra, A., Aregawi, D., Weller, M., Ramakrishnan, V., \u2026 Shih, K. (2019). ACTR-39. PAMIPARIB IN COMBINATION WITH RADIATION THERAPY (RT) AND\/OR TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED OR RECURRENT\/REFRACTORY (R\/R) GLIOBLASTOMA (GBM); PHASE 1B\/2 STUDY UPDATE. Neuro-Oncology, 21, vi21\u2013vi22. https:\/\/doi.org\/10.1093\/neuonc\/noz175.081.","DOI":"10.1093\/neuonc\/noz175.081"},{"key":"10.1016\/j.neuroscience.2026.05.037_b0515","doi-asserted-by":"crossref","unstructured":"Pouyan, A., Ghorbanlo, M., Eslami, M., Jahanshahi, M., Ziaei, E., Salami, A., Mokhtari, K., Shahpasand, K., Farahani, N., Meybodi, T. E., Entezari, M., Taheriazam, A., Hushmandi, K., & Hashemi, M. (2025). Glioblastoma multiforme: insights into pathogenesis, key signaling pathways, and therapeutic strategies. In Molecular Cancer (Vol. 24). BioMed Central Ltd. https:\/\/doi.org\/10.1186\/s12943-025-02267-0.","DOI":"10.1186\/s12943-025-02267-0"},{"key":"10.1016\/j.neuroscience.2026.05.037_b0520","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s40259-018-0267-4","article-title":"Targeting neoantigens for personalised immunotherapy","volume":"32","author":"Pritchard","year":"2018","journal-title":"BioDrugs"},{"key":"10.1016\/j.neuroscience.2026.05.037_b0525","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/sj.bjc.6602665","article-title":"High-level expression of Rad51 is an independent prognostic marker of survival in non-small-cell lung cancer patients","volume":"93","author":"Qiao","year":"2005","journal-title":"Br. J. Cancer"},{"issue":"8","key":"10.1016\/j.neuroscience.2026.05.037_b0530","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1200\/JCO.2008.18.8417","article-title":"Phase II trial of temozolomide plus O6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma","volume":"27","author":"Quinn","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.neuroscience.2026.05.037_b0535","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0027183","article-title":"Rad51 and BRCA2 - new molecular targets for sensitizing glioma cells to alkylating anticancer drugs","volume":"6","author":"Quiros","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.neuroscience.2026.05.037_b0540","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0058206","article-title":"Altered expression of MGMT in high-grade gliomas results from the combined effect of epigenetic and genetic aberrations","volume":"8","author":"Ramalho-Carvalho","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.neuroscience.2026.05.037_b0545","doi-asserted-by":"crossref","unstructured":"Ranger, A. M., Patel, Y. K., Chaudhary, N., & Anantha, R. V. (2014). Familial syndromes associated with intracranial tumours: A review. In Child\u2019s Nervous System (Vol. 30, pp. 47\u201364). Springer Verlag. https:\/\/doi.org\/10.1007\/s00381-013-2309-z.","DOI":"10.1007\/s00381-013-2309-z"},{"key":"10.1016\/j.neuroscience.2026.05.037_b0550","doi-asserted-by":"crossref","unstructured":"Richard, G., Princiotta, M. F., Bridon, D., Martin, W. D., Steinberg, G. D., & De Groot, A. S. (2022). Neoantigen-based personalized cancer vaccines: the emergence of precision cancer immunotherapy. In Expert Review of Vaccines (Vol. 21, pp. 173\u2013184). Taylor and Francis Ltd. https:\/\/doi.org\/10.1080\/14760584.2022.2012456.","DOI":"10.1080\/14760584.2022.2012456"},{"key":"10.1016\/j.neuroscience.2026.05.037_b0555","doi-asserted-by":"crossref","unstructured":"Robertson, A. B., Klungland, A., Rognes, T., & Leiros, I. (2009). Base excision repair: The long and short of it. In Cellular and Molecular Life Sciences (Vol. 66, pp. 981\u2013993). https:\/\/doi.org\/10.1007\/s00018-009-8736-z.","DOI":"10.1007\/s00018-009-8736-z"},{"key":"10.1016\/j.neuroscience.2026.05.037_b0560","doi-asserted-by":"crossref","unstructured":"Sahoo, O. S., Mitra, R., & Nagaiah, N. K. H. (2024). The hidden architects of glioblastoma multiforme: Glioma stem cells. In MedComm - Oncology (Vol. 3). John Wiley and Sons Inc. https:\/\/doi.org\/10.1002\/mog2.66.","DOI":"10.1002\/mog2.66"},{"key":"10.1016\/j.neuroscience.2026.05.037_b0565","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s11060-006-9220-3","article-title":"Expression of nine tumour antigens in a series of human glioblastoma multiforme: interest of EGFRvIII, IL-13R\u03b12, gp100 and TRP-2 for immunotherapy","volume":"81","author":"Saikali","year":"2007","journal-title":"J. Neurooncol"},{"key":"10.1016\/j.neuroscience.2026.05.037_b0570","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1146\/annurev.biochem.77.061306.125255","article-title":"Mechanism of eukaryotic homologous recombination","volume":"77","author":"San Filippo","year":"2008","journal-title":"In Annual Review of Biochemistry (vol."},{"key":"10.1016\/j.neuroscience.2026.05.037_b0575","doi-asserted-by":"crossref","unstructured":"Schiffer, D., Annovazzi, L., Casalone, C., Corona, C., & Mellai, M. (2019). Glioblastoma: Microenvironment and niche concept. In Cancers (Vol. 11). MDPI AG. https:\/\/doi.org\/10.3390\/cancers11010005.","DOI":"10.3390\/cancers11010005"},{"key":"10.1016\/j.neuroscience.2026.05.037_b0580","doi-asserted-by":"crossref","DOI":"10.1007\/s10863-025-10059-w","article-title":"The Warburg hypothesis and the emergence of the mitochondrial metabolic theory of cancer","author":"Seyfried","year":"2025","journal-title":"In Journal of Bioenergetics and Biomembranes. Springer."},{"key":"10.1016\/j.neuroscience.2026.05.037_b0585","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70566","article-title":"Insights into the role of Bmi-1 deregulation in promoting stemness and therapy resistance in glioblastoma: a narrative review","volume":"14","author":"Shaalan","year":"2025","journal-title":"Cancer Med."},{"issue":"1","key":"10.1016\/j.neuroscience.2026.05.037_b0590","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0016146","article-title":"Comprehensive analysis of MGMT promoter methylation: correlation with MGMT expression and clinical response in GBM","volume":"6","author":"Shah","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.neuroscience.2026.05.037_b0595","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The future of immune checkpoint therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.neuroscience.2026.05.037_b0600","doi-asserted-by":"crossref","unstructured":"Shaw, R., Basu, M., Karmakar, S., & Ghosh, M. K. (2024). MGMT in TMZ-based glioma therapy: Multifaceted insights and clinical trial perspectives. In Biochimica et Biophysica Acta - Molecular Cell Research (Vol. 1871, Number 3). Elsevier B.V. https:\/\/doi.org\/10.1016\/j.bbamcr.2024.119673.","DOI":"10.1016\/j.bbamcr.2024.119673"},{"issue":"3","key":"10.1016\/j.neuroscience.2026.05.037_b0605","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1124\/pr.117.014944","article-title":"Current challenges and opportunities in treating glioblastomas","volume":"70","author":"Shergalis","year":"2018","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.neuroscience.2026.05.037_b0610","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aah6816","article-title":"Ibrutinib inactivates BMX-STAT3 in glioma stem cells to impair malignant growth and radioresistance","volume":"10","author":"Shi","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.neuroscience.2026.05.037_b0615","doi-asserted-by":"crossref","unstructured":"Shigdar, S., Li, Y., Bhattacharya, S., O\u2019Connor, M., Pu, C., Lin, J., Wang, T., Xiang, D., Kong, L., Wei, M. Q., Zhu, Y., Zhou, S., & Duan, W. (2014). Inflammation and cancer stem cells. In Cancer Letters (Vol. 345, pp. 271\u2013278). Elsevier Ireland Ltd. https:\/\/doi.org\/10.1016\/j.canlet.2013.07.031.","DOI":"10.1016\/j.canlet.2013.07.031"},{"key":"10.1016\/j.neuroscience.2026.05.037_b0620","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1093\/neuonc\/nor010","article-title":"Rad51 inhibition is an effective means of targeting DNA repair in glioma models and CD133+ tumor-derived cells","volume":"13","author":"Short","year":"2011","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.neuroscience.2026.05.037_b0625","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1215\/15228517-2007-030","article-title":"DNA repair after irradiation in glioma cells and normal human astrocytes","volume":"9","author":"Short","year":"2007","journal-title":"Neuro Oncol."},{"issue":"1","key":"10.1016\/j.neuroscience.2026.05.037_b0630","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s40478-021-01134-5","article-title":"The number of methylated CpG sites within the MGMT promoter region linearly correlates with outcome in glioblastoma receiving alkylating agents","volume":"9","author":"Siller","year":"2021","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.neuroscience.2026.05.037_b0635","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/nature03128","article-title":"Identification of human brain tumour initiating cells","volume":"432","author":"Singh","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.neuroscience.2026.05.037_b0640","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.stem.2009.03.003","article-title":"SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma","volume":"4","author":"Son","year":"2009","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.neuroscience.2026.05.037_b0645","doi-asserted-by":"crossref","DOI":"10.1098\/rsif.2019.0722","article-title":"Mitigating temozolomide resistance in glioblastoma via DNA damage-repair inhibition","volume":"17","author":"Sorribes","year":"2020","journal-title":"J. R. Soc. Interface"},{"key":"10.1016\/j.neuroscience.2026.05.037_b0650","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1128\/MMBR.66.4.630-670.2002","article-title":"Role of RAD52 epistasis group genes in homologous recombination and double-strand break repair","volume":"66","author":"Symington","year":"2002","journal-title":"Microbiol Mol Biol Rev"},{"key":"10.1016\/j.neuroscience.2026.05.037_b0655","article-title":"Epigenetics and metabolism reprogramming interplay into glioblastoma: novel insights on immunosuppressive mechanisms","volume":"12","author":"Torrisi","year":"2023","journal-title":"Antioxidants (Basel, Switzerland)"},{"issue":"7390","key":"10.1016\/j.neuroscience.2026.05.037_b0660","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/nature10866","article-title":"IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype","volume":"483","author":"Turcan","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.neuroscience.2026.05.037_b0665","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1590\/S1807-59322011001000013","article-title":"Correlation of MGMT promoter methylation status with gene and protein expression levels in glioblastoma","volume":"66","author":"Uno","year":"2011","journal-title":"Clinics"},{"key":"10.1016\/j.neuroscience.2026.05.037_b0670","doi-asserted-by":"crossref","unstructured":"Van Tellingen, O., Yetkin-Arik, B., De Gooijer, M. C., Wesseling, P., Wurdinger, T., & De Vries, H. E. (2015). Overcoming the blood-brain tumor barrier for effective glioblastoma treatment. In Drug Resistance Updates (Vol. 19, pp. 1\u201312). Churchill Livingstone. https:\/\/doi.org\/10.1016\/j.drup.2015.02.002.","DOI":"10.1016\/j.drup.2015.02.002"},{"key":"10.1016\/j.neuroscience.2026.05.037_b0675","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ccr.2009.12.020","article-title":"Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1","volume":"17","author":"Verhaak","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.neuroscience.2026.05.037_b0680","doi-asserted-by":"crossref","unstructured":"Vert, G., & Chory, J. (2011). Crosstalk in Cellular Signaling: Background Noise or the Real Thing? In Developmental Cell (Vol. 21, p. 985). Cell Press. https:\/\/doi.org\/10.1016\/j.devcel.2011.11.006.","DOI":"10.1016\/j.devcel.2011.11.006"},{"key":"10.1016\/j.neuroscience.2026.05.037_b0685","doi-asserted-by":"crossref","first-page":"6857","DOI":"10.1007\/s12035-022-02996-z","article-title":"Tumor microenvironment and immune escape in the time course of glioblastoma","volume":"59","author":"Virtuoso","year":"2022","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.neuroscience.2026.05.037_b0690","doi-asserted-by":"crossref","unstructured":"Virtuoso, A., Giovannoni, R., De Luca, C., Gargano, F., Cerasuolo, M., Maggio, N., Lavitrano, M., & Papa, M. (2021). The glioblastoma microenvironment: Morphology, metabolism, and molecular signature of glial dynamics to discover metabolic rewiring sequence. In International Journal of Molecular Sciences (Vol. 22). MDPI AG. https:\/\/doi.org\/10.3390\/ijms22073301.","DOI":"10.3390\/ijms22073301"},{"key":"10.1016\/j.neuroscience.2026.05.037_b0695","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0003769","article-title":"c-Myc is required for maintenance of glioma cancer stem cells","volume":"3","author":"Wang","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.neuroscience.2026.05.037_b0700","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ccell.2021.01.006","article-title":"Proteogenomic and metabolomic characterization of human glioblastoma","volume":"39","author":"Wang","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.neuroscience.2026.05.037_b0705","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ccell.2017.06.003","article-title":"Tumor evolution of glioma-intrinsic gene expression subtypes associates with immunological changes in the microenvironment","volume":"32","author":"Wang","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.neuroscience.2026.05.037_b0710","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.stem.2018.03.011","article-title":"Reciprocal signaling between glioblastoma stem cells and differentiated tumor cells promotes malignant progression","volume":"22","author":"Wang","year":"2018","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.neuroscience.2026.05.037_b0715","doi-asserted-by":"crossref","unstructured":"Wang, Y., Kato, T., Ayaki, H., Lshizaki I, K., & Tano, K. (1992). Correlation between DNA methylation and expression of O6-methylguanine-DNA methyltransferase gene in cultured human tumor cells. In Mutation Research (Vol. 273).","DOI":"10.1016\/0921-8777(92)90083-F"},{"key":"10.1016\/j.neuroscience.2026.05.037_b0720","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1093\/nar\/gkz110","article-title":"MRE11 UFMylation promotes ATM activation","volume":"47","author":"Wang","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.neuroscience.2026.05.037_b0725","article-title":"The emerging roles of Rad51 in cancer and its potential as a therapeutic target","volume":"12","author":"Wang","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.neuroscience.2026.05.037_b0730","unstructured":"Washington University School of Medicine. (2026, March 11). Neoantigen-based Personalized DNA Vaccine With Retifanlimab PD-1 Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma | ClinicalTrials.gov. Https:\/\/Clinicaltrials.Gov\/Study\/NCT05743595. https:\/\/clinicaltrials.gov\/study\/NCT05743595."},{"key":"10.1016\/j.neuroscience.2026.05.037_b0735","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.ijrobp.2020.12.019","article-title":"Focused ultrasound-mediated blood-brain barrier opening increases delivery and efficacy of etoposide for glioblastoma treatment","volume":"110","author":"Wei","year":"2021","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.neuroscience.2026.05.037_b0740","doi-asserted-by":"crossref","DOI":"10.1093\/neuonc\/noaf079","article-title":"A multi-institutional phase 1 clinical trial exploring upfront multimodal standard of care and combined immunotherapies for newly diagnosed glioblastoma","author":"Wen","year":"2025","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.neuroscience.2026.05.037_b0745","first-page":"MDPI","article-title":"Modulating the blood\u2013brain barrier: a comprehensive review","volume":"13, Number 11)","author":"Whelan","year":"2021","journal-title":"In Pharmaceutics (vol."},{"key":"10.1016\/j.neuroscience.2026.05.037_b0750","doi-asserted-by":"crossref","unstructured":"Woo, PeterY. M., Li, Y., Chan, AnnaH. Y., Ng, StephanieC. P., Loong, HerbertH. F., Chan, DannyT. M., Wong, GeorgeK. C., & Poon, W.-S. (2019). A multifaceted review of temozolomide resistance mechanisms in glioblastoma beyond O-6-methylguanine-DNA methyltransferase. Glioma, 2(2), 68. https:\/\/doi.org\/10.4103\/glioma.glioma_{31}9.","DOI":"10.4103\/glioma.glioma_3_19"},{"key":"10.1016\/j.neuroscience.2026.05.037_b0755","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1093\/neuonc\/noq082","article-title":"Glioma cancer stem cells induce immunosuppressive macrophages\/microglia","volume":"12","author":"Wu","year":"2010","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.neuroscience.2026.05.037_b0760","doi-asserted-by":"crossref","unstructured":"Wu, Q., Berglund, A. E., & Etame, A. B. (2021). The impact of epigenetic modifications on adaptive resistance evolution in glioblastoma. In International Journal of Molecular Sciences (Vol. 22). MDPI AG. https:\/\/doi.org\/10.3390\/ijms22158324.","DOI":"10.3390\/ijms22158324"},{"key":"10.1016\/j.neuroscience.2026.05.037_b0765","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s10549-022-06552-0","article-title":"High RAD51 gene expression is associated with aggressive biology and with poor survival in breast cancer","volume":"193","author":"Wu","year":"2022","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.neuroscience.2026.05.037_b0770","doi-asserted-by":"crossref","unstructured":"Xie, N., Shen, G., Gao, W., Huang, Z., Huang, C., & Fu, L. (2023). Neoantigens: promising targets for cancer therapy. In Signal Transduction and Targeted Therapy (Vol. 8). Springer Nature. https:\/\/doi.org\/10.1038\/s41392-022-01270-x.","DOI":"10.1038\/s41392-022-01270-x"},{"key":"10.1016\/j.neuroscience.2026.05.037_b0775","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.canlet.2020.01.011","article-title":"ShRNA-based POLD2 expression knockdown sensitizes glioblastoma to DNA-damaging therapeutics","volume":"482","author":"Xu","year":"2020","journal-title":"Cancer Lett."},{"key":"10.1016\/j.neuroscience.2026.05.037_b0780","first-page":"5788","article-title":"Overexpression of Rad51 predicts poor prognosis and silencing of Rad51 increases chemo-sensitivity to doxorubicin in neuroblastoma","volume":"11","author":"Xu","year":"2019","journal-title":"Am. J. Transl. Res."},{"key":"10.1016\/j.neuroscience.2026.05.037_b0785","unstructured":"Xu, Y. Y., Gao, P., Sun, Y., & Duan, Y. R. (2015). Development of targeted therapies in treatment of glioblastoma. In Cancer Biology and Medicine (Vol. 12, pp. 223\u2013237). Cancer Biology and Medicine. https:\/\/doi.org\/10.7497\/j.issn.2095-3941.2015.0020."},{"key":"10.1016\/j.neuroscience.2026.05.037_b0790","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa0808710","article-title":"IDH1 and IDH2 mutations in gliomas a bs tr ac t. In","volume":"360","author":"Yan","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neuroscience.2026.05.037_b0795","doi-asserted-by":"crossref","unstructured":"Yang, M., Oh, I. Y., Mahanty, A., Jin, W. L., & Yoo, J. S. (2020). Immunotherapy for glioblastoma: Current state, challenges, and future perspectives. In Cancers (Vol. 12, pp. 1\u201323). MDPI AG. https:\/\/doi.org\/10.3390\/cancers12092334.","DOI":"10.3390\/cancers12092334"},{"key":"10.1016\/j.neuroscience.2026.05.037_b0800","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.jmb.2003.12.050","article-title":"p53 inhibits strand exchange and replication fork regression promoted by human Rad51","volume":"336","author":"Yoon","year":"2004","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.neuroscience.2026.05.037_b0805","doi-asserted-by":"crossref","unstructured":"Zhang, A., Miao, K., Sun, H., & Deng, C. X. (2022). Tumor heterogeneity reshapes the tumor microenvironment to influence drug resistance. In International Journal of Biological Sciences (Vol. 18, pp. 3019\u20133033). Ivyspring International Publisher. https:\/\/doi.org\/10.7150\/ijbs.72534.","DOI":"10.7150\/ijbs.72534"},{"key":"10.1016\/j.neuroscience.2026.05.037_b0810","doi-asserted-by":"crossref","unstructured":"Zhang, J., Stevens, M. F. G., & Bradshaw, T. D. (2012). Temozolomide: Mechanisms of Action, Repair and Resistance. In Current Molecular Pharmacology (Vol. 5).","DOI":"10.2174\/1874467211205010102"},{"key":"10.1016\/j.neuroscience.2026.05.037_b0815","doi-asserted-by":"crossref","first-page":"e14025","DOI":"10.1200\/JCO.2024.42.16_suppl.e14025","article-title":"Personalized neoantigen-pulsed autologous dendritic cells vaccine as an adjuvant treatment for patients with newly-diagnosed glioblastoma multiforme: a phase I trial","volume":"42","author":"Zhang","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.neuroscience.2026.05.037_b0820","doi-asserted-by":"crossref","unstructured":"Zheng, J., Wang, Y., Liang, Q., Cui, L., & Wang, L. (2024). The Application of Machine Learning on Antibody Discovery and Optimization. In Molecules (Vol. 29). Multidisciplinary Digital Publishing Institute (MDPI). https:\/\/doi.org\/10.3390\/molecules29245923.","DOI":"10.3390\/molecules29245923"},{"key":"10.1016\/j.neuroscience.2026.05.037_b0825","doi-asserted-by":"crossref","DOI":"10.1186\/s13578-021-00575-8","article-title":"Glioblastoma stem cell (GSC)-derived PD-L1-containing exosomes activates AMPK\/ULK1 pathway mediated autophagy to increase temozolomide-resistance in glioblastoma","volume":"11","author":"Zheng","year":"2021","journal-title":"Cell and Bioscience"},{"key":"10.1016\/j.neuroscience.2026.05.037_b0830","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s40364-024-00679-6","article-title":"Advances in CAR-T therapy for central nervous system tumors","volume":"12","author":"Zhou","year":"2024","journal-title":"Biomarker Res."},{"key":"10.1016\/j.neuroscience.2026.05.037_b0835","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.109369","article-title":"Increased expression of MMP-2 and MMP-9 indicates poor prognosis in glioma recurrence","volume":"118","author":"Zhou","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.neuroscience.2026.05.037_b0840","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-16066-1","article-title":"Yeast display biopanning identifies human antibodies targeting glioblastoma stem-like cells","volume":"7","author":"Zorniak","year":"2017","journal-title":"Sci. Rep."}],"container-title":["Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030645222600360X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030645222600360X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T16:13:24Z","timestamp":1784132004000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030645222600360X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":168,"alternative-id":["S030645222600360X"],"URL":"https:\/\/doi.org\/10.1016\/j.neuroscience.2026.05.037","relation":{},"ISSN":["0306-4522"],"issn-type":[{"value":"0306-4522","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Understanding resistance in glioblastoma: insights into personalized and targeted therapeutic strategies","name":"articletitle","label":"Article Title"},{"value":"Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuroscience.2026.05.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Brain Research Organization (IBRO). Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}